Decentralized Clinical Trials Market to Hit $29.37 Billion by 2034 as AI and Chronic Disease Demand Accelerate
Updated
Updated · Fortune Business Insights · Jun 15
Decentralized Clinical Trials Market to Hit $29.37 Billion by 2034 as AI and Chronic Disease Demand Accelerate
1 articles · Updated · Fortune Business Insights · Jun 15
Summary
USD 29.37 billion is the projected size of the global decentralized clinical trials market by 2034, up from USD 9.56 billion in 2025 and USD 10.92 billion in 2026, implying a 13.2% CAGR.
AI-enabled analytics, telemedicine, wearables and remote monitoring are driving adoption by speeding patient identification, trial matching, enrollment planning and retention, especially in complex oncology, neurology and rare-disease studies.
Services led the market in 2025, while hybrid decentralized trials and phase III studies also dominated; oncology was the top therapeutic area, and pharmaceutical and biotechnology companies were the largest end users.
North America remained the biggest region with USD 4.06 billion in 2025, while China is estimated at USD 0.97 billion in 2026 as sponsors expand trial activity into developing markets.
High implementation costs, platform integration problems, cybersecurity needs and limited trial infrastructure in some emerging countries still threaten wider rollout despite stronger demand.
Will AI-powered 'digital twins' soon make human participation in some clinical trials obsolete?
As clinical trials move into patients' homes, what unseen risks to safety and data integrity are emerging?
With fragmented global regulations, how can a single decentralized trial ensure it remains fully compliant across all borders?
Decentralized Clinical Trials Market Outlook 2026–2035: Growth Drivers, Regulatory Shifts, and the Digital Transformation of Patient-Centric Research
Overview
As of mid-2026, the Decentralized Clinical Trials (DCTs) market is expanding rapidly, fueled by strong investments from pharmaceutical companies, biotechnology firms, and contract research organizations. This growth is supported by a favorable regulatory environment, a shift toward patient-centric research, and the widespread adoption of digital health technologies like AI and machine learning. The COVID-19 pandemic accelerated the adoption of DCTs, highlighting their value in making clinical research more efficient, inclusive, and cost-effective. As a result, decentralized trials are becoming increasingly important in advancing global clinical research.